COMMUNIQUÉS West-GlobeNewswire

Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis
08/01/2019
Communiqué de presse Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis ................................................. 8 janvier 2019 - [...]
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
08/01/2019
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered by multi-cell adhesion [...]
Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco
08/01/2019
NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial [...]
Scheme becomes effective
08/01/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
08/01/2019
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
08/01/2019
LA JOLLA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering
07/01/2019
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today [...]
Canopy Rivers Announces $80 Million Bank Debt Facility at PharmHouse
07/01/2019
TORONTO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV: RIV) today announced that its 49%-owned joint venture PharmHouse Inc. (“ PharmHouse ”) has entered into a [...]
Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019
07/01/2019
CINCINNATI, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to [...]
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
07/01/2019
reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader focus on digital [...]
The Cooper Companies Declares Cash Dividend
07/01/2019
PLEASANTON, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced that consistent with the plan approved by its board of directors to pay annual dividends, the Company declared [...]
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
07/01/2019
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments [...]
Ziopharm Oncology Posts Letter to Stockholders
07/01/2019
BOSTON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us [...]
Medexus Files Business Acquisition Report
07/01/2019
MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “ Company ” ) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on [...]
Medexus présente une déclaration d’acquisition
07/01/2019
MONTRÉAL, 07 janv. 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « Société ») (TSXV : MDP, OTCQB : PDDPF) a annoncé aujourd’hui la présentation d’une déclaration d’acquisition [...]
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
07/01/2019
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, thoracic, lung, gastrointestinal [...]
Nanobiotix et le MD Anderson Cancer Center annoncent une collaboration clinique globale de grande envergure portant sur NBTXR3
07/01/2019
La collaboration comporte dans un premier temps neuf nouveaux essais cliniques de phase I/II avec NBTXR3, premier produit d’une nouvelle classe de Nanobiotix, dans six types de cancer différents - cancers de la tête et [...]
Holding(s) in Company
07/01/2019
Holding(s) in Company January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shire Plc JE00B2QKY057 1b. [...]
eSight Proudly Announces 40% Price Reduction on Breakthrough Electronic Glasses for The Visually Impaired —Marking Its Largest Affordability Advancement Ever
07/01/2019
Rapid growth makes price reduction from $9,500 USD to $5,950 USD possible, providing greater accessibility to life-changing, vision-enhancing, and mobility-enabling device for the visually impaired TORONTO and LOS [...]

Pages